PMID- 28363412
OWN - NLM
STAT- MEDLINE
DCOM- 20170801
LR  - 20210317
IS  - 1347-8648 (Electronic)
IS  - 1347-8613 (Print)
IS  - 1347-8613 (Linking)
VI  - 133
IP  - 3
DP  - 2017 Mar
TI  - FTY720-derivatives do not induce FTY720-like lymphopenia.
PG  - 187-189
LID - S1347-8613(17)30021-X [pii]
LID - 10.1016/j.jphs.2017.02.006 [doi]
AB  - FTY720 is an immunosuppressive multiple sclerosis (MS) drug that stimulates the 
      expression of neuroprotective brain-derived-neurotrophic-factor (BDNF). In vivo 
      preclinical data suggest that FTY720 could be beneficial for treating Parkinson's 
      patients, though its immunosuppressive effects might limit its efficacy. Two 
      novel FTY720-derivatives, FTY720-C2 and FTY720-Mitoxy, also stimulate BDNF 
      expression and enter brain like FTY720 but are not phosphorylated, suggesting 
      they will not produce FTY720-like immunosuppression. Using FTY720 as a positive 
      control, we measured low and high dose FTY720-derivatives, which did not 
      stimulate FTY720-like lymphopenia or immunosuppressive signaling. These findings 
      support the further preclinical assessment of the derivatives as potential novel 
      Parkinson's therapies.
CI  - Copyright (c) 2017 The Authors. Production and hosting by Elsevier B.V. All rights 
      reserved.
FAU - Segura-Ulate, Ismael
AU  - Segura-Ulate I
AD  - Department of Biomedical Sciences, Graduate School of Biomedical Sciences, Center 
      of Emphasis in Neurosciences, Paul L. Foster School of Medicine, Texas Tech 
      University Health Sciences Center El Paso, El Paso, TX, United States.
FAU - Belcher, Troy K
AU  - Belcher TK
AD  - Department of Biomedical Sciences, Graduate School of Biomedical Sciences, Center 
      of Emphasis in Neurosciences, Paul L. Foster School of Medicine, Texas Tech 
      University Health Sciences Center El Paso, El Paso, TX, United States.
FAU - Vidal-Martinez, Guadalupe
AU  - Vidal-Martinez G
AD  - Department of Biomedical Sciences, Graduate School of Biomedical Sciences, Center 
      of Emphasis in Neurosciences, Paul L. Foster School of Medicine, Texas Tech 
      University Health Sciences Center El Paso, El Paso, TX, United States.
FAU - Vargas-Medrano, Javier
AU  - Vargas-Medrano J
AD  - Department of Biomedical Sciences, Graduate School of Biomedical Sciences, Center 
      of Emphasis in Neurosciences, Paul L. Foster School of Medicine, Texas Tech 
      University Health Sciences Center El Paso, El Paso, TX, United States.
FAU - Perez, Ruth G
AU  - Perez RG
AD  - Department of Biomedical Sciences, Graduate School of Biomedical Sciences, Center 
      of Emphasis in Neurosciences, Paul L. Foster School of Medicine, Texas Tech 
      University Health Sciences Center El Paso, El Paso, TX, United States. Electronic 
      address: ruth.g.perez@ttuhsc.edu.
LA  - eng
GR  - D43 TW008333/TW/FIC NIH HHS/United States
PT  - Journal Article
DEP - 20170217
PL  - Japan
TA  - J Pharmacol Sci
JT  - Journal of pharmacological sciences
JID - 101167001
RN  - 0 (Receptors, Lysosphingolipid)
RN  - 0 (S1pr1 protein, mouse)
RN  - 0 (Sphingosine-1-Phosphate Receptors)
RN  - NGZ37HRE42 (Sphingosine)
SB  - IM
MH  - Animals
MH  - Cell Line, Tumor
MH  - Female
MH  - Leukocyte Count
MH  - Lymphocytes/*drug effects
MH  - Lymphopenia
MH  - MAP Kinase Signaling System/drug effects
MH  - Male
MH  - Mice, Inbred C57BL
MH  - Neutrophils/drug effects
MH  - Phosphorylation
MH  - Receptors, Lysosphingolipid/metabolism
MH  - Sphingosine/analogs & derivatives/*pharmacology
MH  - Sphingosine-1-Phosphate Receptors
PMC - PMC7959251
MID - NIHMS1676489
OTO - NOTNLM
OT  - Anti-inflammatory
OT  - Fingolimod
OT  - Neuroprotection
COIS- Conflict of interest statement The corresponding author has filed a patent, 
      "Compositions and Methods for the Treatment of Parkinson's Disease", US 
      20150290145, CA 2888634, which does not alter adherence to Journal of 
      Pharmacological Sciences policies.
EDAT- 2017/04/02 06:00
MHDA- 2017/08/02 06:00
PMCR- 2021/03/15
CRDT- 2017/04/02 06:00
PHST- 2016/11/08 00:00 [received]
PHST- 2017/02/02 00:00 [revised]
PHST- 2017/02/06 00:00 [accepted]
PHST- 2017/04/02 06:00 [pubmed]
PHST- 2017/08/02 06:00 [medline]
PHST- 2017/04/02 06:00 [entrez]
PHST- 2021/03/15 00:00 [pmc-release]
AID - S1347-8613(17)30021-X [pii]
AID - 10.1016/j.jphs.2017.02.006 [doi]
PST - ppublish
SO  - J Pharmacol Sci. 2017 Mar;133(3):187-189. doi: 10.1016/j.jphs.2017.02.006. Epub 
      2017 Feb 17.